$PCYN
PROCYON CORP Stock $pcyn

$pcyn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000143774922023194 Filed on September 28, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$1.176M	$1.209M	$4.842M
YoY Change	-1.2%	-4.44%	2.6%
Cost Of Revenue	$294.9K	$332.2K	$1.357M
YoY Change	-10.16%	-12.92%	1.93%
Gross Profit	$880.8K	$877.1K	$3.486M
YoY Change	2.21%	-0.79%	2.87%
Gross Profit Margin	74.92%	72.53%	71.98%
Selling, General & Admin	$424.1K	$983.7K	$1.711M
YoY Change	19.0%	0.08%	28.6%
% of Gross Profit	48.15%	112.15%	49.07%
Research & Development			$30.00K
YoY Change			-2.91%
% of Gross Profit			0.86%
Depreciation & Amortization	$10.91K	$10.40K	$38.22K
YoY Change	32.84%	19.4%	-11.8%
% of Gross Profit	1.24%	1.19%	1.1%
Operating Expenses	$424.1K	$983.7K	$1.741M
YoY Change	19.0%	0.08%	27.88%
Operating Profit	-$11.45K	-$106.6K	-$237.2K
YoY Change	-117.38%	7.8%	-173.04%
Interest Expense	$895.00	$330.00	$0.00
YoY Change	141.89%	-184.62%
% of Operating Profit
Other Income/Expense, Net	$895.00	$0.00	$1.804K
YoY Change	141.24%	-100.0%	-99.64%
Pretax Income	-$10.56K	-$106.3K	-$235.4K
YoY Change	-115.94%	-125.99%	-128.3%
Income Tax	-$2.371K	-$26.90K	-$25.62K
% Of Pretax Income
Net Earnings	-$8.187K	-$79.36K	-$209.8K
YoY Change	-119.27%	-117.54%	-127.33%
Net Earnings / Revenue	-0.7%	-6.56%	-4.33%
Basic Earnings Per Share	$0.00		-$0.03
Diluted Earnings Per Share	$0.00	-$9.813K	-$0.03
COMMON SHARES
Basic Shares Outstanding	8.087M	8.087M	8.087M
Diluted Shares Outstanding	8.087M		8.087M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$865.8K	$1.042M	$1.042M
YoY Change	-33.19%	-30.89%	-30.89%
Cash & Equivalents	$584.5K	$760.4K
Short-Term Investments	$281.3K	$281.1K	$281.1K
Other Short-Term Assets	$249.1K	$374.8K	$374.8K
YoY Change	-10.39%	35.68%	35.68%
Inventory	$775.9K	$761.7K	$761.7K
Prepaid Expenses
Receivables	$527.2K	$407.1K	$407.1K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.418M	$2.585M	$2.585M
YoY Change	-17.39%	-9.98%	-9.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$149.8K	$153.7K	$859.9K
YoY Change	23.25%	40.66%	-13.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$340.4K	$340.6K	$340.6K
YoY Change	-6.18%	-11.98%	-11.98%
Total Long-Term Assets	$1.169M	$1.217M	$1.217M
YoY Change	-12.81%	-12.76%	-12.76%
TOTAL ASSETS
Total Short-Term Assets	$2.418M	$2.585M	$2.585M
Total Long-Term Assets	$1.169M	$1.217M	$1.217M
Total Assets	$3.586M	$3.802M	$3.803M
YoY Change	-15.95%	-10.89%	-10.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$114.9K	$178.1K	$178.1K
YoY Change	-54.77%	6.26%	6.26%
Accrued Expenses	$362.6K	$465.2K	$465.2K
YoY Change	-24.25%	-18.11%	-18.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$477.5K	$643.2K	$643.2K
YoY Change	-34.83%	-12.56%	-12.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$449.1K	$491.3K	$491.3K
YoY Change	-26.84%	-24.86%	-24.86%
Total Long-Term Liabilities	$449.1K	$491.3K	$491.3K
YoY Change	-26.84%	-24.86%	-24.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$477.5K	$643.2K	$643.2K
Total Long-Term Liabilities	$449.1K	$491.3K	$491.3K
Total Liabilities	$926.7K	$1.135M	$1.135M
YoY Change	-31.19%	-18.35%	-18.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.947M	-$1.939M
YoY Change	15.44%	12.13%
Common Stock	$4.445M	$4.445M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.660M	$2.668M	$2.668M
YoY Change
Total Liabilities & Shareholders Equity	$3.586M	$3.802M	$3.803M
YoY Change	-15.95%	-10.89%	-10.89%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$8.187K	-$79.36K	-$209.8K
YoY Change	-119.27%	-117.54%	-127.33%
Depreciation, Depletion And Amortization	$10.91K	$10.40K	$38.22K
YoY Change	32.84%	19.4%	-11.8%
Cash From Operating Activities	-$128.9K	$10.46K	-$229.5K
YoY Change	-15.56%	-91.23%	-182.1%
INVESTING ACTIVITIES
Capital Expenditures	$7.003K	-$22.61K	$82.64K
YoY Change	-65.8%	-50.86%	26.82%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$7.003K	-$22.61K	-$82.64K
YoY Change	-65.8%	-103.62%	-117.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$40.00K	-37.44K	-$154.0K
YoY Change	5.55%	40.96%	-22.58%
NET CHANGE
Cash From Operating Activities	-$128.9K	10.46K	-$229.5K
Cash From Investing Activities	-$7.003K	-22.61K	-$82.64K
Cash From Financing Activities	-$40.00K	-37.44K	-$154.0K
Net Change In Cash	-$175.9K	-49.59K	-$466.1K
YoY Change	-16.65%	-106.91%	-183.13%
FREE CASH FLOW
Cash From Operating Activities	-$128.9K	$10.46K	-$229.5K
Capital Expenditures	$7.003K	-$22.61K	$82.64K
Free Cash Flow	-$135.9K	$33.07K	-$312.1K
YoY Change	-21.5%	-79.99%	-245.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	13569	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9408	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	496000000
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	496000000
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8087388
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8087388
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8087388
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8087388
CY2022	pcyn	Increase Decrease In Operating Lease Rightofuse Asset IncreaseDecreaseInOperatingLeaseRightofuseAsset	180109.37	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	180109.37	usd
CY2022	pcyn	Percentage Of Discount On Bill Payment Within Ten Days To Pharmaceutical Distributors And Drug Stores PercentageOfDiscountOnBillPaymentWithinTenDaysToPharmaceuticalDistributorsAndDrugStores	0.02	pure
CY2022	pcyn	Percentage Of Discount On Bill Payment Within Ten Days To Physicians PercentageOfDiscountOnBillPaymentWithinTenDaysToPhysicians	0.02	pure
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2535	pure
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-17449
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3280822
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	164 Douglas Rd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Oldsmar
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34677
CY2022	dei	City Area Code CityAreaCode	727
CY2022	dei	Local Phone Number LocalPhoneNumber	447-2998
CY2022	dei	Security12g Title Security12gTitle	Common Stock
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	1370828	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8087388
CY2022	dei	Auditor Name AuditorName	Ferlita, Walsh, Gonzalez & Rodriguez, P.A.
CY2022	dei	Auditor Firm AuditorFirmId	232
CY2022	dei	Auditor Location AuditorLocation	Tampa, FL
CY2022Q2	us-gaap	Cash Cash	760396	usd
CY2021Q2	us-gaap	Cash Cash	1226522	usd
CY2022Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	281105	usd
CY2021Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	280438	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	407085	usd
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	497358	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	761651	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	591058	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	374817	usd
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	276251	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2585054	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	2871627	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153702	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109275	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	12311	usd
CY2021Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3235	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	182224	usd
CY2021Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	263280	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17000	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	706155	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	882344	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	146051	usd
CY2021Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	120430	usd
CY2022Q2	pcyn	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	1063741	usd
CY2021Q2	pcyn	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	1286289	usd
CY2022Q2	us-gaap	Assets Assets	3802497	usd
CY2021Q2	us-gaap	Assets Assets	4267191	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	178083	usd
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	167588	usd
CY2022Q2	pcyn	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	302601	usd
CY2021Q2	pcyn	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	413977	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	162547	usd
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	154022	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	643231	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	735587	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	491312	usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	653860	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	491312	usd
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	653860	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1134543	usd
CY2021Q2	us-gaap	Liabilities Liabilities	1389447	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	4444766	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	4444766	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35564	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35564	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1939236	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1729446	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2667954	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2877744	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3802497	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4267191	usd
CY2022	us-gaap	Revenues Revenues	4842433	usd
CY2021	us-gaap	Revenues Revenues	4719672	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1356612	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1330979	usd
CY2022	us-gaap	Gross Profit GrossProfit	3485821	usd
CY2021	us-gaap	Gross Profit GrossProfit	3388693	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	2012430	usd
CY2021	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1831804	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1710606	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1330215	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3723036	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3162019	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-237215	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	226674	usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	304887	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	203172	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1804	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1232	usd
CY2022	us-gaap	Interest Expense InterestExpense	-0	usd
CY2021	us-gaap	Interest Expense InterestExpense	2172	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1804	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	507119	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-235411	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	733793	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25621	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39444	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-209790	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	694349	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-226500	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	677639	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8319624
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2877744	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	42482	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	2920226	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-67562	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2852664	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-105348	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2747316	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-79362	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2667954	usd
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	2163716	usd
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	219096	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	2382812	usd
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	74313	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2457125	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	21714	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	2478839	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19679	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	379226	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2877744	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-209790	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	694349	usd
CY2022	us-gaap	Depreciation Depreciation	38217	usd
CY2021	us-gaap	Depreciation Depreciation	43331	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4161	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	pcyn	Operating Lease Right Of Use Asset Amortization Expense Reversal OperatingLeaseRightOfUseAssetAmortizationExpenseReversal	176189	usd
CY2021	pcyn	Operating Lease Right Of Use Asset Amortization Expense Reversal OperatingLeaseRightOfUseAssetAmortizationExpenseReversal	120981	usd
CY2022	pcyn	Accrued Interest On Certificates Of Deposit AccruedInterestOnCertificatesOfDeposit	667	usd
CY2021	pcyn	Accrued Interest On Certificates Of Deposit AccruedInterestOnCertificatesOfDeposit	306	usd
CY2022	pcyn	Deferred Income Tax Expense Benefit Gross DeferredIncomeTaxExpenseBenefitGross	-57581	usd
CY2021	pcyn	Deferred Income Tax Expense Benefit Gross DeferredIncomeTaxExpenseBenefitGross	184063	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-31960	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	144619	usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-0	usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	304887	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	203172	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	19679	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-86112	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	186315	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	9076	usd
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-957	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	89537	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12010	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	98566	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	93113	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10495	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	129	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2172	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-111376	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	158261	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-229459	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	279500	usd
CY2022	pcyn	Payments For Purchases Of Cd PaymentsForPurchasesOfCD		usd
CY2021	pcyn	Payments For Purchases Of Cd PaymentsForPurchasesOfCD	125000	usd
CY2022	pcyn	Payments For Redemption Of Certificates Of Deposit PaymentsForRedemptionOfCertificatesOfDeposit	-0	usd
CY2021	pcyn	Payments For Redemption Of Certificates Of Deposit PaymentsForRedemptionOfCertificatesOfDeposit	-0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82644	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65166	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	670303	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82644	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	480137	usd
CY2022	pcyn	Operating Lease Principal Payments OperatingLeasePrincipalPayments	154023	usd
CY2021	pcyn	Operating Lease Principal Payments OperatingLeasePrincipalPayments	198949	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-154023	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-198949	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-466126	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1226522	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	665834	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	560688	usd
CY2022	pcyn	Standard Payment Term To Physicians StandardPaymentTermToPhysicians	P30D
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13600	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	9400	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	760396	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1226522	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	pcyn	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2	pure
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Concentration of Credit Risk</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company maintains its cash at various financial institutions. All accounts are fully insured by the Federal Deposit Insurance Corporation, up to <em style="font: inherit;">$250,000</em> per Company. At <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021,</em> our uninsured cash balance was $52,539 and $30 respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	52539	usd
CY2021Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	30	usd
CY2022	pcyn	Term Of Sale For Pharmaceutical Distributors And Drug Stores TermOfSaleForPharmaceuticalDistributorsAndDrugStores	P30D
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	65000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.17
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.37
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	115000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.26
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	115000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.26
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	759118	usd
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	683771	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	184757	usd
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	170567	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	943875	usd
CY2021Q2	us-gaap	Inventory Gross InventoryGross	854338	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	182224	usd
CY2021Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	263280	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	426745	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	426745	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	273043	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	-0	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	273043	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153702	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	153702	usd
CY2022	us-gaap	Depreciation Depreciation	38217	usd
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	365063	usd
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	usd
CY2021Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	365063	usd
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	255788	usd
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	-0	usd
CY2021Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	255788	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109275	usd
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2021Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	109275	usd
CY2021	us-gaap	Depreciation Depreciation	43331	usd
CY2022Q2	us-gaap	Share Price SharePrice	0.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.8381	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	151341	usd
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	131187	usd
CY2022Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	41837	usd
CY2021Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	29899	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	53681	usd
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	50916	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	10789	usd
CY2021Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	153494	usd
CY2022Q2	pcyn	Accrued Lease Liability AccruedLeaseLiability	40439	usd
CY2021Q2	pcyn	Accrued Lease Liability AccruedLeaseLiability	38620	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4514	usd
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9861	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	302601	usd
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	413977	usd
CY2019Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2021Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	31091	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19679	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-209790	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	694349	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-226500	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	677639	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-226500	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	677639	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	65136
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	167100
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8319624
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	822000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-21229	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	32681	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4392	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	6763	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-25621	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	39444	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	208277	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4988	usd
CY2022Q2	pcyn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	164727	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	10604	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	2734	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	3439	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	394769	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	177981	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	38777	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	216758	usd
CY2022Q2	pcyn	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	178011	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	146051	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-31960	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2535	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-49436	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	154097	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10229	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	31883	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	689	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3450	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	0	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	51494	usd
CY2022	pcyn	Effective Income Tax Rate Reconciliation Loss Carryforward Amount EffectiveIncomeTaxRateReconciliationLossCarryforwardAmount	-1395	usd
CY2021	pcyn	Effective Income Tax Rate Reconciliation Loss Carryforward Amount EffectiveIncomeTaxRateReconciliationLossCarryforwardAmount	-46127	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	31960	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-144619	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25621	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39444	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30900	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	973081	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	266926	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	706155	usd
CY2015Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	973081	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	319222	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	653859	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	162547	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	491312	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	208467	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	133531	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M26D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0329	pure

Files In Submission

Name	View Source	Status
0001437749-22-023194-index-headers.html	Edgar Link	pending
0001437749-22-023194-index.html	Edgar Link	pending
0001437749-22-023194.txt	Edgar Link	pending
0001437749-22-023194-xbrl.zip	Edgar Link	pending
ex_426985.htm	Edgar Link	pending
ex_426986.htm	Edgar Link	pending
ex_426987.htm	Edgar Link	pending
ex_426988.htm	Edgar Link	pending
ex_426989.htm	Edgar Link	pending
ex_426990.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcyn-20220630.xsd	Edgar Link	pending
pcyn20220630_10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
pcyn-20220630_cal.xml	Edgar Link	unprocessable
pcyn-20220630_def.xml	Edgar Link	unprocessable
pcyn-20220630_lab.xml	Edgar Link	unprocessable
pcyn-20220630_pre.xml	Edgar Link	unprocessable
pcyn20220630_10k_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCYN
PROCYON CORP Stock $pcyn

2022 Q3 Form 10-K Financial Statement

#000143774922023194 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCYN PROCYON CORP Stock $pcyn

2022 Q3 Form 10-K Financial Statement

#000143774922023194 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCYN
PROCYON CORP Stock $pcyn